This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.

Alterations in inhibitory circuits and difficulties in social recognition characterize mice missing one copy of DYRK1A, a gene linked to autism.

After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.

A protective pathway that pauses protein synthesis is muted in a mouse model of fragile X syndrome, according to a new study.

The new devices, which monitor neural activity from within blood vessels, show long-term stability in rats and could one day deliver electrical stimulation.

The inhibitory cells misfire and contribute to social difficulties in mice that model the syndrome.

Here is a roundup of news and research for the week of 26 June.

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.

The tool connects to electrodes implanted in people with epilepsy or other brain conditions and can monitor and regulate neurons during everyday activities.